Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
Gavoille, A., Rollot, F., Casey, R., Debouverie, M., Le Page, E., Ciron, J., De Seze, J., Ruet, A., Maillart, E., Labauge, P., et al. (2022). Neurology p.10.1212/WNL.0000000000206774

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
Sabathé, C., Casey, R., Vukusic, S., Leray, E., Mathey, G., De Sèze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., et al. (2022). Mult Scler p.13524585221139156

Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease
Carra-Dallière, C., Rollot, F., Deschamps, R., Ciron, J., Vukusic, S., Audoin, B., Ruet, A., Maillart, E., Papeix, C., Zephir, H., et al. (2022). Mult Scler p.13524585221134214

Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients
Lescot, L., Lefort, M., Leguy, S., Le Page, E., Vukusic, S., Edan, G., Kerbrat, A., Lebrun-Frenay, C., De Sèze, J., Laplaud, D.A., et al. (2022). Mult Scler Relat Disord (68). p.104122

Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach
Salem, M., Ryan, M.A., Oliver, A., Hussain, K.F., and Lladó, X. (2022). Front Neurosci (16). p.1007619

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients
Leguy, S., Lefort, M., Lescot, L., Michaud, A., Vukusic, S., Le Page, E., Edan, G., Kerbrat, A., Lebrun-Frenay, C., De Sèze, J., et al. (2022). J Neurol (269). p.5571–5581

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Signori, A., Lorscheider, J., Vukusic, S., Trojano, M., Iaffaldano, P., Hillert, J., Hyde, R., Pellegrini, F., Magyari, M., Koch-Henriksen, N., et al. (2022). J Neurol Neurosurg Psychiatry p.jnnp-2022-329987

Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry
Simoneau, G., Jiang, X., Rollot, F., Tian, L., Copetti, M., Guéry, M., Ruiz, M., Vukusic, S., de Moor, C., Pellegrini, F., et al. (2022). Mult Scler J Exp Transl Clin (8). p.20552173221116590

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Roos, I., Malpas, C., Leray, E., Casey, R., Horakova, D., Havrdova, E.K., Debouverie, M., Patti, F., De Seze, J., Izquierdo, G., et al. (2022). Neurology p.10.1212/WNL.0000000000201029

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Lefort, M., Sharmin, S., Andersen, J.B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., et al. (2022a). BMC Med Res Methodol (22). p.155

Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments
Lefort, M., Vukusic, S., Casey, R., Edan, G., Leray, E., and OFSEP investigators (2022b). Eur J Neurol

Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera
El Khoury, Y., Gebelin, M., de Sèze, J., Patte-Mensah, C., Marcou, G., Varnek, A., Mensah-Nyagan, A.-G., Hellwig, P., and Collongues, N. (2022). Int J Mol Sci (23). p.2791

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
Demuth, S., Guillaume, M., Bourre, B., Ciron, J., Zephir, H., Sirejacob, Y., Kerbrat, A., Lebrun-Frenay, C., Papeix, C., Michel, L., et al. (2022). J Neuroinflammation (19). p.62

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal
Rollot, F., Couturier, J., Casey, R., Wiertlewski, S., Debouverie, M., Pelletier, J., De Sèze, J., Labauge, P., Ruet, A., Thouvenot, E., et al. (2022). Neurotherapeutics

Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients
Lefort, M., Le Corre, G., Le Page, E., Rizzato, C., Le Port, D., Michel, L., Kerbrat, A., Leray, E., and Edan, G. (2022c). Rev Neurol (Paris) p.S0035-3787(22)00043-1

Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study
Papeix, C., Castelnovo, G., Leray, E., Coustans, M., Levy, P., Visy, J.-M., Kobelt, G., Lamy, F., Allaf, B., Heintzmann, F., et al. (2022). Neurol Ther